Table of contents


Precision or imprecision medicine?

Lisa Hutchinson & Diana Romero

p713 | doi:10.1038/nrclinonc.2016.190


Research Highlights

Lung cancer: Anti-PD-1 therapy in the frontline | PDF (164 KB)

p715 | doi:10.1038/nrclinonc.2016.170

Immunotherapy: Novel modified T cells enable more-specific tumour targeting | PDF (186 KB)

p716 | doi:10.1038/nrclinonc.2016.169

Immunotherapy: More gain, less pain | PDF (255 KB)

p716 | doi:10.1038/nrclinonc.2016.180

Breast cancer: MONALEESA-2 and FALCON — PFS advantage | PDF (261 KB)

p717 | doi:10.1038/nrclinonc.2016.174

In the news: From ESMO 2016 | PDF (80 KB)

p718 | doi:10.1038/nrclinonc.2016.172

Kidney cancer: New approaches for high-risk disease | PDF (206 KB)

p718 | doi:10.1038/nrclinonc.2016.173


News and Views

Targeted therapies: What have we learned from SHIVA?

Christophe Le Tourneau & Razelle Kurzrock

p719 | doi:10.1038/nrclinonc.2016.164

The SHIVA trial compared the efficacy of targeted agents selected on the basis of tumour molecular profiling (using an algorithmic approach) with that of physician's choice across multiple solid tumours; the trial was negative for the primary end point. We now discuss the challenges associated with precision medicine trial design and propose solutions learned from this trial.

Health policy: HPV vaccination in boys — will the UK join the fight?

Liam Masterson & Matt Lechner

p721 | doi:10.1038/nrclinonc.2016.184

The UK Joint Committee on Vaccination and Immunization recently announced a further delay before considering the subject of widespread human papillomavirus (HPV) vaccination in teenage boys, thereby excluding an estimated 2.9 million boys from receiving an effective treatment in this interim period. Vaccination of boys can offer significant clinical, economic and ethical advantages.

Lung cancer: Best supportive care — a reasonable option for patients with brain metastases?

Dirk Rades & Steven E. Schild

p722 | doi:10.1038/nrclinonc.2016.179

Most patients with cancer who develop brain metastases have a very poor prognosis, especially those with brain metastases from non-small-cell lung cancer. The short life-expectancy of these patients, which is typically measured in weeks or a few months, raises an important question: do they benefit from whole-brain radiotherapy, or are they appropriately treated with best supportive care alone? A recent randomized trial sought to answer this question.



Non-invasive metabolic imaging of brain tumours in the era of precision medicine

Michelle M. Kim, Abhijit Parolia, Mark P. Dunphy & Sriram Venneti

p725 | doi:10.1038/nrclinonc.2016.108

Many of the molecular pathways that are aberrant in brain tumours result in reprogramming of metabolism, which creates opportunities for in vivo metabolic imaging to improve diagnosis, patient stratification, and disease monitoring. Herein, the molecular basis and strategies for non-invasive metabolic imaging of brain tumours are reviewed.

Improving early diagnosis of symptomatic cancer

Willie Hamilton, Fiona M. Walter, Greg Rubin & Richard D. Neal

p740 | doi:10.1038/nrclinonc.2016.109

Expediting the diagnosis of cancer is generally considered to result in improved patient outcomes, and much effort is applied to achieving this goal. Herein, the authors describe the various aspects of early diagnosis of cancer including the potential benefits, methods, most suitable patients and likely costs, in the context of the UK National Health Service.

Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer

Pavan P. Adiseshaiah, Rachael M. Crist, Sara S. Hook & Scott E. McNeil

p750 | doi:10.1038/nrclinonc.2016.119

Intrinsic pathophysiological barriers limit the delivery of drugs to pancreatic cancers, contributing to the limited effectiveness of treatment. Nanomedicine approaches have the potential to overcome many of these drug-delivery challenges, and two nanoparticle therapies are now approved for the treatment of this disease. The authors discuss the key pathobiological barriers that must be overcome, the approaches to nanomedicine that have been pursued to date, and those that are the focus of ongoing research.




The role of Internet resources in clinical oncology: promises and challenges

Bradford W. Hesse, Alexandra J. Greenberg & Lila J. Finney Rutten

p767 | doi:10.1038/nrclinonc.2016.78

The Internet is a valuable tool that continues to revolutionize many aspects of our lives. Herein, the current trends in the use of online resources in oncology are described, using the findings from the National Cancer Institute's Health Information National Trends Survey (HINTS) as a foundation. Future opportunities and challenges relating to the use of the Internet to improve cancer prevention and care are discussed.

Extra navigation


Subscribe to Nature Reviews Clinical Oncology